Abstract
Abstract The combination of immune checkpoint blockage (ICB) agent and chemotherapy for cancer treatment is gaining lots of attention lately. However, there is no clear biomarker or index for such treatment, particularly after tumor gaining resistance to ICI. In this study, an improved hollow fiber assay (HFA) was utilized based upon a novel substrate of microtube array membrane (MTAM) to test the possible patient response towards the combined treatment of immunotherapy and chemotherapy. In this case study, biopsy of a stage 4 adenocarcinoma (cT2N3M1b) patient, with the disease progression after a durable response to prior pemetrexed and Nivolumab, was retrieved and treated with enzyme for a homogenous cell suspension. Pieces of MTAM preloaded with 106 of cancer cell along with patient’s peripheral blood mononuclear cell (PBMC) were implanted subcutaneously in bulb C mice. These mice were grouped and subjected to two different ICB combinational treatments (1) Nivolumab with Paclitaxel and (2) Nivolumab with Pemetrexed. 10 days later MTAMs were explanted and cancer cells were subject to MTT assay for their viability. The results of two treatments clearly demonstrated the better efficacy of Nivolumab and Paclitaxel towards this patient cancer cells. Clinically, CT images taken before and after a two-month treatment show positive response towards the combinational treatment of Nivolumab and Paclitaxel. This case study suggests a rapid clinical regiment prediction/selection of ICB combinational treatment is possible in two weeks using MTAM/HFA and provides reasonable evident for the corresponding treatment. Citation Format: Kang-Yun Lee, Chien-Chung Chen, Won-Ting Huang. Rapid personalized selection of immune checkpoint blockage agent combinational treatment for an adenocarcinoma patient [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2253.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
